Earnings guidance isn't what it used to be.
News & Analysis: Endologix
The market slams the company's shares after news breaks that its next-generation system won't be coming to market anytime soon.
It's been a dark time for the medical device maker, but some lights at the end of the tunnel gave investors a reason to cheer last month.
The CE Mark of approval has been reinstated for the company's AFX and AFX2 endovascular AAA systems.
A voluntary hold on production of its top seller has been lifted, allowing for shipments to return to normal.
The FDA is pushing back its timeline for considering approval of the company's Nellix system.
A potential delay in approving Nellix in the U.S. is weighing on investors' minds.
How Endologix, Edwards Lifesciences, and Veeva are winning while many stocks aren't.
An acquisition and notes offering offset better-than-hoped third-quarter results.
Endologix sales and guidance suffers from currency-related headwinds.